28.24
28.24 (0.03%)
As of Aug 09, 2022
Intersect Ent, Inc. [XENT]
Source:
Company Overview
Intersect Ent, Inc is a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care. Our U.S. Food and Drug Administration (“FDA”) approved steroid releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease.
| Country | United States |
| Headquarters | menlo park, california |
| Phone Number | 650-641-2100 |
| Industry | manufacturing |
| CEO | Thomas A. West |
| Website | intersectent.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $21.6 |
| Operating Profit | $-26.7 |
| Net Income | $-28.8 |
| Net Cash | $-13.8 |
Profit Ratios
| Gross Margin | $13.9 |
| Operating Margin | -123.6 |
| Profit as % of Revenues | -48.2% |
| Profit as % of Assets | -21% |
| Profit as % of Stockholder Equity | 30.6% |
Management Effectiveness
| Return on Equity | 30.6% |
| Return on Assets | -22.6% |
| Turnover Ratio | 15.7% |
| EBITA | $-26.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $127.4 |
| Total Liabilities | $221.4 |
| Operating Cash Flow | $-26.9 |
| Investing Cash Flow | $-2.7 |
| Financing Cash Flow | $15.8 |
